Analyst Ratings for Spring Works Therapeutics (SWTX)
SWTX Rating Summary
SWTX Price Target Summary
- Highest: $94.00 (H.C. Wainwright)
- Lowest: $50.00 (Wedbush)
- Average: $79.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$79.50 (+180.5%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/22/2021 | Goldman Sachs » Updated 5/24/2022 |
Corinne Jenkins | New Coverage | Buy (N/A) |
82.00 (76.00) |
68.20 (28.34) |
-58.45% | Details |
| 5/5/2020 | Barclays » Updated 2/26/2021 |
Peter Lawson | New Coverage | Overweight (N/A) |
105.00 (92.00) |
30.21 (28.34) |
-6.19% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
SWTX Ratings News
- UPDATE: Spring Works Therapeutics (SWTX) PT Lowered to $50 at Wedbush
- JPMorgan Reiterates $92 PT on Spring Works Therapeutics (SWTX), 'we continue to see underappreciated fundamental value with nirogacestat in desmoid tumors and BCMA programs'
- Spring Works Therapeutics (SWTX) PT Lowered to $121 at Goldman Sachs
- See More
